Table 3.
Hazard ratio for in-hospital mortality in the full cohort by AC treatment duration, dosage and type in sensitivity analyses.
| No. of in-hospital death/total no. (%) | Crude HR (95% CI) | Adjusted* HR (95% CI) | Adjusted* HR for IPTW model# (95% CI) | |
|---|---|---|---|---|
| Non-AC treatment | 91/2002 (4.5) | Reference | Reference | Reference |
| Duration | ||||
| AC treatment <7 days | 44/78 (56.4) | 13.600 (9.482–19.507) | 3.424 (2.242–5.230) | 1.018 (0.742–1.399) |
| AC treatment for 7 days or longer | 38/192 (19.8) | 2.881 (1.943–4.272) | 0.864 (0.560–1.335) | 0.164 (0.104–0.260) |
| Dosage | ||||
| Low dose thromboprophylaxis | 43/176 (24.4) | 4.354 (3.020–6.277) | 1.387 (0.923–2.085) | 0.498 (0.329–0.754) |
| Intermediate dose thromboprophylaxis | 21/55 (38.2) | 6.702 (4.153–10.816) | 1.492 (0.870–2.560) | 0.349 (0.224–0.545) |
| Therapeutic dose anticoagulation | 18/39 (46.2) | 6.959 (4.131–11.723) | 1.575 (0.905–2.742) | 0.225 (0.132–0.384) |
| Type | ||||
| LMWH | 80/262 (30.5) | 5.120 (3.878–7.162) | 1.432 (1.004–2.043) | 0.382 (0.271–0.537) |
| Non-LMWH | 2/8 (25.0) | 3.590 (0.866–14.884) | 2.029 (0.482–8.538) | 0.094 (0.019–0.466) |
*
Adjusted for baseline covariates including age, gender, levels of platelets count, prothrombin time, D-dimer, total bilirubin, lactate dehydrogenase, urea, and high-sensitivity C reactive protein.
#
Covariates in IPTW model: level of oxygen therapy, clinical classification, high-sensitivity C reactive protein and D-dimer levels, Platelet count at admission, CURB-65 score at hospital admission, and the highest level of oxygen therapy during hospitalization.
AC, anticoagulation; HR, hazard ratio; CI, confidence interval; IPTW, inverse probability of treatment weighting analysis; LMWH, low molecular weight heparin.